Viatris downgraded to Market Perform from Outperform at BMO Capital

BMO Capital analyst Gary Nachman downgraded Viatris to Market Perform from Outperform with a price target of $14, down from $16. The company is progressing well with its strategic initiatives to create additional value, but the stock could be range-bound pending execution on the next phase of its evolution, the analyst tells investors in a research note. The firm sees a lack of visibility on the timing of Viatris’s next divestitures and uncertainty around the peak potential for its newly acquired Eye Care franchise.